Journal of Oncology

Changes in Cell Signaling Pathways as a Goal of Targeted Therapy of Solid Tumors


Publishing date
01 Jun 2020
Status
Closed
Submission deadline
31 Jan 2020

1Medical University of Lublin, Lublin, Poland

2University of Kragujevac, Kragujevac, Serbia

3Medical University of Białystok, Białystok, Poland

This issue is now closed for submissions.
More articles will be published in the near future.

Changes in Cell Signaling Pathways as a Goal of Targeted Therapy of Solid Tumors

This issue is now closed for submissions.
More articles will be published in the near future.

Description

There has been an increased incidence of cancer in both men and women followed by increased mortality over the past 40 years. Approximately 10% of cancers occurring in the human population are caused by genetic predispositions, that is, hereditary gene defects which highlight the significant effect of environmental factors on cancerogenesis. Modern principles of cancerogenesis involve multistage processes in the development of cancer in which many conditions must be met. The correct functioning of the cell is primarily dependent on the correct functioning of the signaling proteins stimulated by the appropriate receptors.

Tyrosine kinase signaling is one of most important signaling pathways which controls multiple aspects of cell and organism growth, differentiation, proliferation, and function. Therefore, altered levels of activity of tyrosine kinase group receptors are commonly associated with many human cancers and their activity is manipulated through targeted therapy. Drugs inhibit signaling pathways resulting in cell growth arrest and apoptosis and additionally bind to the external receptors which mediate Antibody-Dependent Cellular Cytotoxicity (ADCC).

Mutations in tumor cells cause alterations in protein receptors and subsequently the activation of signaling pathways such as RAS-RAF-MAPK (mitogen-activated protein kinase), PIK3-AKT-mTOR (inhibitors phosphatidylinositol 3′ kinase-serine/threonine-specific protein kinase-mammalian target of rapamycin), JAK-STAT (signal transducer and activator of transcription), and protein kinase C. The signal cascade of Ras/Raf/MEK/ERK is widely known and the possibility of blocking the cascade in tumor cells provides a potential foundation for the introduction of new drugs and targeted therapy in oncology.

The proper function of signaling pathways is responsible for cell differentiation, growth, aging, apoptosis, and angiogenesis. Studies related to the signaling pathway may develop understanding based on the nature of tumor progression. Knowledge of the mechanisms involved on a molecular level behind the processes of cancer formation and progression is essential for the development of effective therapy methods.

Potential topics include but are not limited to the following:

  • The role of receptors overexpression for signaling pathways in cancer
  • New possibilities in target therapy
  • The changes in signaling pathways in cancer
  • Oncogene overexpression and their influence on signal pathways in cancer
  • Factors influencing signal transduction in cancer
  • Deconstructing signaling pathways and optimizing cancer combination therapies

Articles

  • Special Issue
  • - Volume 2020
  • - Article ID 3656841
  • - Research Article

Genetic Profiles Playing Opposite Roles of Pathogenesis in Schizophrenia and Glioma

Ya-Dan Wen | Zhi-Wei Xia | ... | Hui Cao
  • Special Issue
  • - Volume 2020
  • - Article ID 3181596
  • - Research Article

HEATR1 Deficiency Promotes Chemoresistance via Upregulating ZNF185 and Downregulating SMAD4 in Pancreatic Cancer

Yuan Fang | Xu Han | ... | Wenhui Lou
  • Special Issue
  • - Volume 2020
  • - Article ID 1973241
  • - Review Article

EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis

Vladimir Jurisic | Vladimir Vukovic | ... | Nataša Djordjević
  • Special Issue
  • - Volume 2020
  • - Article ID 9258396
  • - Review Article

Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR

Miguel A. Ortega | Oscar Fraile-Martínez | ... | Santiago Coca
  • Special Issue
  • - Volume 2020
  • - Article ID 8797683
  • - Research Article

Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy

Monika Bilska | Anna Pawłowska | ... | Iwona Wertel
  • Special Issue
  • - Volume 2020
  • - Article ID 5291952
  • - Review Article

AXL as a Target in Breast Cancer Therapy

Sierra A. Colavito
  • Special Issue
  • - Volume 2019
  • - Article ID 2902985
  • - Research Article

Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy

Sabrina Borchert | Pia-Maria Suckrau | ... | Fabian D. Mairinger
  • Special Issue
  • - Volume 2019
  • - Article ID 5956867
  • - Review Article

mTOR-Mediated Antioxidant Activation in Solid Tumor Radioresistance

Yunseo Woo | Hyo-Ji Lee | ... | Yu-Jin Jung
  • Special Issue
  • - Volume 2019
  • - Article ID 2684075
  • - Research Article

Whole-Exome Sequencing Characterized the Landscape of Somatic Mutations and Pathways in Colorectal Cancer Liver Metastasis

Liuxing Feng | Shifu Hong | ... | Jiayi Li
Journal of Oncology
 Journal metrics
Acceptance rate24%
Submission to final decision66 days
Acceptance to publication37 days
CiteScore1.400
Impact Factor2.206
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.